Abstract

The WWE domain is a relatively under-researched domain found in twelve human proteins and characterized by a conserved tryptophan-tryptophan-glutamate (WWE) sequence motif. Six of these WWE domain-containing proteins also contain domains with E3 ubiquitin ligase activity. The general recognition of poly-ADP-ribosylated substrates by WWE domains suggests a potential avenue for development of Proteolysis-Targeting Chimeras (PROTACs). Here, we present novel crystal structures of the HUWE1, TRIP12, and DTX1 WWE domains in complex with PAR building blocks and their analogs, thus enabling a comprehensive analysis of the PAR binding site structural diversity. Furthermore, we introduce a versatile toolbox of biophysical and biochemical assays for the discovery and characterization of novel WWE domain binders, including fluorescence polarization-based PAR binding and displacement assays, 15N-NMR-based binding affinity assays and 19F-NMR-based competition assays. Through these assays, we have characterized the binding of monomeric iso-ADP-ribose (iso-ADPr) and its nucleotide analogs with the aforementioned WWE proteins. Finally, we have utilized the assay toolbox to screen a small molecule fragment library leading to the successful discovery of novel ligands targeting the HUWE1 WWE domain.

Six WWE domain-containing proteins also contain domains with E3 ubiquitin ligase activity. We report structures, biophysical and biochemical assays for the discovery of novel WWE domain binders and their respective application.

Details

Title
A ligand discovery toolbox for the WWE domain family of human E3 ligases
Author
Münzker, Lena 1 ; Kimani, Serah W. 2   VIAFID ORCID Logo  ; Fowkes, Milan M. 3   VIAFID ORCID Logo  ; Dong, Aiping 4 ; Zheng, Hong 4 ; Li, Yanjun 4   VIAFID ORCID Logo  ; Dasovich, Morgan 5 ; Zak, Krzysztof M. 1 ; Leung, Anthony K. L. 5   VIAFID ORCID Logo  ; Elkins, Jonathan M. 3 ; Kessler, Dirk 1   VIAFID ORCID Logo  ; Arrowsmith, Cheryl H. 6   VIAFID ORCID Logo  ; Halabelian, Levon 7   VIAFID ORCID Logo  ; Böttcher, Jark 1   VIAFID ORCID Logo 

 Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria (GRID:grid.486422.e) (ISNI:0000000405446183) 
 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.415224.4) (ISNI:0000 0001 2150 066X) 
 University of Oxford, Centre for Medicines Discovery, Nuffield Department of Medicine, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 Johns Hopkins University, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311) 
 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); Princess Margaret Cancer Centre, Toronto, Canada (GRID:grid.415224.4) (ISNI:0000 0001 2150 066X); University of Toronto, Department of Medical Biophysics, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
 University of Toronto, Structural Genomics Consortium, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, Department of Pharmacology and Toxicology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938) 
Pages
901
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3084107199
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.